PRECLINICAL PHARMACOLOGY OF A NEW SEROTONERGIC RECEPTOR ANTAGONIST, LY281067

被引：0
|
作者：
COHEN, ML
FULLER, RW
KURZ, KD
PARLI, CJ
MASON, NR
MEYERS, DB
SMALLWOOD, JK
TOOMEY, RE
机构：
来源：
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 1988年 / 244卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：106 / 112
页数：7
相关论文
共 50 条
  • [31] THE PRECLINICAL PHARMACOLOGY OF ICI-204,219 - A PEPTIDE LEUKOTRIENE ANTAGONIST
    KRELL, RD
    AHARONY, D
    BUCKNER, CK
    KEITH, RA
    KUSNER, EJ
    SNYDER, DW
    BERNSTEIN, PR
    MATASSA, VG
    YEE, YK
    BROWN, FJ
    HESP, B
    GILES, RE
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1990, 141 (04): : 978 - 987
  • [32] Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010
    Werner, U.
    ANNALES D ENDOCRINOLOGIE, 2008, 69 (02) : 164 - 165
  • [33] Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA)
    McNamara, Alexander
    Steinfeld, Tod
    Pulido-Rios, Maria Teresa
    Stangeland, Eric
    Hegde, Sharath S.
    Mammen, Mathai
    Martin, William J.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2012, 25 (05) : 357 - 363
  • [34] Preclinical Pharmacology and Pharmacokinetics of AZD3783, a Selective 5-Hydroxytryptamine 1B Receptor Antagonist
    Zhang, Minli
    Zhou, Diansong
    Wang, Yi
    Maier, Donna L.
    Widzowski, Daniel V.
    Sobotka-Briner, Cynthia D.
    Brockel, Becky J.
    Potts, William M.
    Shenvi, Ashok B.
    Bernstein, Peter R.
    Pierson, M. Edward
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (02): : 567 - 578
  • [35] SEROTONERGIC RECEPTOR ANTAGONIST FROM NANDINA-DOMESTICA THUNBERG
    SHOJI, N
    UMEYAMA, A
    TAKEMOTO, T
    OHIZUMI, Y
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (04) : 568 - 570
  • [36] Interaction of the beta receptor adrenergic antagonist bucindolol with serotonergic receptors
    Fink, GD
    Watts, SW
    Silver, P
    Cushing, DJ
    FASEB JOURNAL, 1999, 13 (05): : A1114 - A1114
  • [37] Androgen receptor antagonists: Lead optimization and preclinical pharmacology
    Gavai, Ashvin
    Norris, Derek
    Balog, Aaron
    Austin, Joel
    Shan, Weifang
    Zhao, Yufen
    Han, Wen-Ching
    Sharma, Lisa
    Nation, Andrew
    Wu, Dauh-Rurng
    Mathur, Arvind
    Zhang, Litai
    Cvijic, Mary Ellen
    Yarde, Melissa
    Apanovitch, Donald
    Twamley, Celeste
    Tang, Yuwei
    Johnson, Benjamin
    Elzinga, Paul
    Cornelius, Georgia
    Obermeier, Mary
    Foster, William
    Marathe, Punit
    Dell-John, Janet
    Dito, Gennaro
    Masters, Gregg
    Rizzo, Cheryl
    Schweizer, Liang
    Jure-Kunkel, Maria
    Attar, Ricardo
    Gottardis, Marco
    Vite, Gregory
    CANCER RESEARCH, 2010, 70
  • [38] New opioid receptor antagonist: Naltrexone-14-O-sulfate synthesis and pharmacology
    Zador, Ferenc
    Kiraly, Kornel
    Varadi, Andras
    Balogh, Mihaly
    Feher, Agnes
    Kocsis, Dora
    Erdei, Anna I.
    Lacko, Erzsebet
    Zadori, Zoltan S.
    Hosztafi, Sandor
    Noszal, Bela
    Riba, Pal
    Benyhe, Sandor
    Furst, Susanna
    Al-Khrasani, Mahmoud
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 809 : 111 - 121
  • [39] Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data
    Nilvebrant, L
    Hallen, B
    Larsson, G
    LIFE SCIENCES, 1997, 60 (13-14) : 1129 - 1136
  • [40] The in vitro pharmacology of LY IGlar (LY2963016): a new insulin glargine product
    Moyers, J. S.
    Kahl, S. D.
    Ruan, X.
    Zhang, C.
    Farmen, M. W.
    Michael, M. D.
    Owens, R. A.
    DIABETOLOGIA, 2015, 58 : S255 - S255
12345